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Abstract 25 
In an effort to eradicate malaria, new interventions are proposed to include 26 
compound/vaccine development against pre-erythrocytic, erythrocytic and mosquito 27 
stages of Plasmodium. Drug repurposing might be an alternative approach to new 28 
antimalarials reducing the cost and the time required for drug development. Previous 29 
in vitro studies have examined the effects of protease inhibitors on different stages of 30 
the Plasmodium parasite, although the clinical relevance of this remains unclear. In 31 
this study we tested the putative effect of three HIV protease inhibitors, two general 32 
aspartyl protease inhibitors and three AAA-p97 ATPase inhibitors on the zygote to 33 
ookinete transition of the Plasmodium parasite. Apart from the two general aspartyl 34 
inhibitors, all other compounds had a profound effect on the development of the 35 
parasites. HIVPIs inhibited zygote to ookinete conversion by 75%-90%, while the three 36 
AAA-p97 ATPase inhibitors blocked conversion by 50%-90% at similar 37 
concentrations, while electron microscopy highlighted nuclear and structural 38 
abnormalities. Our results highlight a potential of HIV protease inhibitors and p97 39 
inhibitors as transmission blocking agents for the eradication of malaria. 40 
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Despite all efforts to control and eradicate malaria, the disease still poses a 51 
major burden on human health. Drug resistance together with the absence of an 52 
effective vaccine has worsened the prospects for a “malaria-free” world. New 53 
antimalarial drugs are thus urgently needed, but the ultimate target of blocking malaria 54 
is no longer considered a one-goal strategy. Malaria transmission blockage could be 55 
theoretically achieved through the effective elimination of gametocytes from the 56 
bloodstream rendering human hosts non-infective to mosquitoes, or by interfering with 57 
the early parasite development inside the vector (gamete and zygote/ookinete stages).  58 
Thus far though, transmission stages of Plasmodium parasites have largely 59 
been unexplored in drug screening approaches. Nevertheless, gametes, zygotes and 60 
ookinetes in the mosquito midgut lumen, are vulnerable stages, metabolically active, 61 
unprotected by the host cell membrane and exposed to the hostile environment of the 62 
mosquito midgut. In this study we tested the putative effect of 8 compounds, which 63 
belong to 3 distinct classes of inhibitors, on the zygote to ookinete transition that takes 64 
place in the mosquito midgut immediately after gamete fertilization and is an attractive 65 
target for the development of transmission blocking strategies. For this, we have used 66 
the rodent malaria model, Plasmodium berghei, where these stages differentiate 67 
efficiently in vitro under defined experimental conditions [1]. 68 
The first class of compounds includes 3 HIV protease inhibitors (HIVPIs); 69 
Nelfinavir, Ritonavir and Lopinavir. HIVPIs are specific protease inhibitors of the HIV 70 
aspartyl protease, which has an essential role in the generation of mature infectious 71 
virus particles [2]. Numerous studies over the last ten years have highlighted the 72 
inhibitory effect of HIVPIs on pre-erythrocytic stages and the asexual development of 73 
different Plasmodium species and also on gametocytogenesis, exflagellation and 74 
viability of gametocytes, while also affecting mosquito infectivity [3-5]. Their effect 75 
though on zygote to ookinete transition has not yet been examined. Since HIVPIs 76 
inhibit the aspartyl protease of the HIV virus we also included two general aspartyl 77 
protease inhibitors; pepstatin A, which is known to inhibit intra-erythrocytic growth of 78 
Plasmodium spp. but has no effect on P. gallinaceum ookinete development in vitro 79 
[6] and diazo-acetyl-norleucinemethylester (DAN), which has not been previously 80 
tested in Plasmodium spp. cultures but has been used in in vitro proliferation assays 81 
in L. Mexicana. In the presence of DAN, parasites had alterations in shape, from a 82 
long slender form to a spherical one and cell division was blocked [7]. The last family 83 
includes 3 compounds, which target the ERAD pathway by inhibiting the action of an 84 
AAA ATPase (p97). Previous studies in mammalian cells have shown that 85 
Eeyarestatin 1 (Eer) is a bi-modular compound comprised from two functionally 86 
independent domains: an aromatic module (CBU) that targets ES to membranes, and 87 
a nitrofuran-containing module (5-NA). The compounds tested here were, Eer, CBU-88 
028 and 5-nitrofuryl acrolein (NA), which consists of the nitrofuran domain of Eer [8]. 89 
Eer has been shown to inhibit growth of Plasmodium falciparum asexual stages with 90 
IC50 values of 3.5 μM [9]. 91 
To assess the transmission blocking potential of these compounds, the 92 
P.berghei CTRP-GFP strain was used that specifically expresses GFP after zygote 93 
formation thus making feasible the identification of toxicity of the tested compounds in 94 
early stages of development by FACS analysis [10]. All compounds used were added 95 
after formation of the zygote and were present in the in vitro cultures throughout 96 
ookinete development. Our results showed that only lopinavir at 50 μM and NA at 35 97 
and 50 μM, had a significant toxic effect on parasite survival. The highest 98 
concentration of NA has been excluded from further studies. In all other treatments 99 
GFP levels were not statistically different relative to control cultures (Fig. 1A). Giemsa 100 
stained smears of purified cultures were used to quantify the effect of each drug on 101 
the conversion rate of zygotes to ookinetes and to identify the stage of arrest judged 102 
by the morphology of the parasites. 35 μM of nelfinavir and ritonavir decreased 103 
development to mature ookinetes by 85% and 75%, respectively. At 50 μM both drugs 104 
caused an almost complete arrest at zygote/retort stages. Lopinavir treatment at 35 105 
and 50 μM led to an arrest at stage I-II for the vast majority of parasites (~90%) (Fig. 106 
1B). Eer had also a profound effect on the zygote/ookinete transition at 35 and 50 μM, 107 
arresting parasites at stage I-II, a pattern also observed with NA at 10 μM. 35 μM of 108 
NA led to an arrest in stage I zygotes (90%). Maximum inhibition exerted by CBU-028 109 
was at 50 μM, while at 35 μM, 50% of parasites progressed to mature ookinetes. From 110 
these data it seems plausible that the nitrofuran moiety is responsible for the effect 111 
seen on zygote/ookinete transition. Surprisingly Pepstatin A and DAN had no effect 112 
on ookinete development at any concentration used in our study.   113 
To determine the infectivity of the drug-treated cells, purified ookinetes from in 114 
vitro cultures were offered to mosquitoes in standard membrane feeding assays 115 
(SMFA). As shown in Fig. 1C, in the presence of HIVPIs very few oocysts are formed 116 
in the mosquito midguts suggesting that the ookinetes might have developmental 117 
defects that render them unable to establish an infection in the mosquito, as was the 118 
case with the p97 inhibitors. Treatment with pepstatin A and DAN, on the other hand, 119 
did not result in lower oocyst numbers compared to the DMSO-treated control.  120 
Immunofluorescence assays using specific antibodies were performed to 121 
further investigate the defects in ookinetes derived from in vitro cultures to which the 122 
the HIVPIs and the p97 inhibitors had been added. The nuclear protein SET displayed 123 
no obvious abnormal pattern in treated parasites with the exception of nelfinavir where 124 
the pattern of SET looks fragmented (Fig. 2A). The surface protein p28, in all cases 125 
but with varying degrees, was found in the cytoplasm indicating a possible defect in 126 
the trafficking of p28 to the surface of the ookinetes (Fig. 2A). The micronemal protein 127 
SOAP was present in the treated parasites, exhibiting though a more diffuse pattern 128 
throughout the cytoplasm in parasites treated with the different p97 inhibitors (Fig. 2B).  129 
In order to further examine the cellular defects TEM was employed. The apical 130 
complex (AC) of HIV-treated parasites was detected in some cases, albeit in early 131 
stages of development (Fig. 2C-ritonavir). Micronemes were detectable in the 132 
cytoplasm (Fig. 2C, nelfinavir, lopinavir), and IMC was present in treated parasites. In 133 
contrast, the nuclear membrane seemed to be distorted in nelfinavir treated parasites, 134 
with expanded nuclei. Lopinavir treated parasites are characterized by extensive 135 
vacuolation. Parasites treated with the p97 inhibitors show vacuoles throughout the 136 
cytoplasm. A key characteristic though in all cases is the extended membrane 137 
structures around the nucleus, a possible effect of prolonged ER stress, which has 138 
been previously shown to induce changes in the structure of the ER [8, 11]. 139 
Our study on the effect of 8 compounds on the early mosquito stages of the 140 
malaria parasite have shown a potent negative effect of HIVPIs and p97 inhibitors on 141 
ookinete formation. Consequently oocyst formation was significantly decreased when 142 
these parasites were offered to mosquitoes. The target(s) of HIVPIs in Plasmodium 143 
spp have yet to be identified. The initial hypothesis of them targeting the vacuolar 144 
aspartyl proteases termed plasmepsins in erythrocytic stages (plasmepsin I, II, II, IV), 145 
which are responsible for the haemoglobin degradation, has proven wrong, since their 146 
effect persists in mutant knock-out parasites [12]. In the case of P. falciparum, two 147 
transporters (PfHT and PfCRT) have been suggested as potential targets of lopinavir 148 
and saquinavir respectively [13, 14], alongside the plasmepsin family but data are far 149 
from conclusive. The lack of any effect with pepstatin A in our SMFA is not in 150 
agreement with the previous study in P. gallinaceum but in their experimental set up, 151 
infected blood with gametocytes was offered to the mosquitoes instead of purified 152 
ookinetes [6]. This might suggest that pepstatin A has an effect on gametocytes or 153 
gametogenesis. Overall, our results suggest that a Plasmodium aspartyl protease is 154 
not the primary target of HIV protease inhibitors on the zygote/ookinete conversion 155 
stage. 156 
P97 inhibitors have not been extensively interrogated in Plasmodium as only 157 
Eer and another reversible inhibitor of p97, DBeQ, have been examined in in vitro P. 158 
falciparum cultures. This study showed that Plasmodium parasites have a very basic 159 
ERAD machinery compared to mammalian cells and thus they are much more 160 
sensitive to specific compounds that were designed to inhibit their mammalian 161 
molecular targets [15]. 162 
Although one would expect that HIVPIs and p97 inhibitors are quite distinct in 163 
their mode of action and on their molecular targets, they do share some interesting 164 
similarities.  HIVPIs, mainly nelfinavir, ritonavir and saquinavir, have been repurposed 165 
for cancer treatment and clinical trials are currently ongoing with nelfinavir being 166 
predominantly the drug of choice [16]. But what is that makes HIVPIs promising 167 
candidates for anti-cancer treatment? HIVPIs and particularly nelfinavir have been 168 
shown to inhibit the Akt kinase pathway and also induce ER stress leading to activation 169 
of the unfolded protein response pathway (UPR). Inhibition of the ERAD pathway with 170 
the use of p97 inhibitors also leads to UPR activation [11, 17]. The inhibition of kinases 171 
by nelfinavir raises an interesting observation as a similar mis-localisation of p28 172 
(Figure 2A) has been observed in CDPK1 mutant parasites [18]. Could it be that 173 
nelfinavir inhibits CDPK1 or other kinases thus affecting trafficking of this surface 174 
antigen? Further studies are necessary to validate this observation. Overall, in 175 
Plasmodium spp, it seems more plausible that the severe effects of HIVPIs on all 176 
stages of the life cycle might be attributed to the off targets of the drugs by inhibition 177 
of kinases or by acting as general ER stressors. Further studies are needed in order 178 
to identify the potential molecular targets of each class of compounds (HIVPIs or p97 179 
inhibitors).  180 
The early mosquito stages are attractive targets for transmission blocking 181 
agents, as they take place soon after uptake of a blood meal by the mosquito and they 182 
are still present in the mammalian blood meal. Many groups are pursuing this path 183 
with a substantial amount of work been done for the identification of targets and 184 
inhibitors. Bumped kinase inhibitors are a good example of potential transmission 185 
blocking agents since they can prevent exflagellation of gametocytes in P. falciparum 186 
in the nM range and preliminary studies show a blockade in oocyst formation in 187 
mosquitoes [19]. There are however substantial challenges. Drugs to be given to the 188 
human host (HIVPIs for example), should be stable for a long period required for 189 
gametocyte maturation and in high concentrations, which will require new formulations 190 
and drug delivery strategies. Building on already available drugs, new scaffolds might 191 
provide better pharmacokinetic properties, or development of prodrugs could 192 
significantly enhance bioavailability. One could envisage HIVPIs per se, or as starting 193 
points for compound development, to be used for parallel application in malaria/HIV 194 
coinfection or as antimalarial drugs and transmission blocking compounds. 195 
The approach of targeting the parasite in the vector is yet a largely unexplored 196 
option. Although the vector is not an obvious system for drug delivery, alternative 197 
approaches can be pursued to deliver drugs directly to the mosquito [20]. Recent 198 
advances in nanoparticle technology in combination with the development of sugar 199 
traps to attract mosquitoes might provide an alternative route for targeting the parasite. 200 
Studies in P. falciparum using drug containing liposomes have provided some 201 
interesting data and could pave the way for new nanoparticles to be used as carriers 202 
for drugs or transmission blocking agents [21] The results presented here suggest that 203 
HIVPI’s should be interrogated as suitable compounds for such strategies.  204 
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Figure legends 304 
Figure 1  305 
A. Cytotoxic effect of compounds on P.berghei ookinete development.  306 
HIVPIs were obtained from Sequoia Research products Ltd. Diazoacetyl-DL-307 
norleucine methyl ester (DAN) and pepstatin A were purchased from Sigma-Aldrich. 308 
Stocks (×1000) were prepared in DMSO. Dilutions of the drug were carried out in 309 
culture medium. CTRP-GFP expressing P.berghei ookinete cultures were analysed 310 
using FACS. For the in vitro ookinete cultures, blood from 2-3 mice was pooled, 311 
leucocytes removed and the blood was diluted 1:10 in ookinete medium (RPMI1640 312 
containing 25 mM HEPES (Sigma), 10% FCS, 100 µM xanthurenic acid, pH 7.5). 313 
Samples were dispensed in 6 well-plates, incubated for 1h at 18°C, after which the 314 
drug or DMSO alone, was added. After incubation at 18°C for 24h, ookinete cultures 315 
were enriched and concentrated by Nycodenz gradient centrifugation. Increasing 316 
concentrations of the compounds were added after formation of the zygote and were 317 
present throughout ookinete development. Cell viability measured in Relative 318 
Fluorescence Units is shown relative to control. Bars represent means ± SE from three 319 
independent experiments. Asterisk symbols on columns indicate differences between 320 
control and compound treated groups. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05 (one-way 321 
ANOVA followed by Dunett’s multiple comparison test).  322 
B. Phenotypic analysis of compound treated ookinete cultures. Compounds were 323 
added to the ookinete cultures after zygote formation and 18-24hrs after fertilisation 324 
purified parasites were stained with Giemsa and observed under light microscope 325 
(1000x). Morphologies of Giemsa stained untreated and treated parasites were 326 
grouped in four categories (stage I, II, III-IV, V-VI). Representative pictures of each 327 
stage are shown. Different morphological shapes were recorded in 12-15 optical fields 328 
in three independent experiments. The majority of control parasites have transformed 329 
to elongated ookinetes but compound treated parasites failed to reach this stage in 330 
the case of HIV-PIs and p97 inhibitors. Aspartyl-protease specific inhibitors do not 331 
affect parasite transition to mature ookinetes.  332 
C. Infectivity of compound treated P.berghei ookinetes. An. gambiae mosquitoes 333 
were fed using SMFA with DMSO (control) or compound treated P. berghei ookinetes. 334 
Enriched ookinetes, treated with drugs as mentioned above, were mixed in fresh blood 335 
from naive mice at a density of 3-5x103 ookinetes/μL. Graphs illustrate three 336 
independent experiments. Each dot represents the number of oocysts counted per 337 
individual An. gambiae midgut 6 days after feeding. The horizontal lines indicate the 338 
median numbers of oocysts. Error bars represent the interquartile range. Statistical 339 
significance between control and compound treated groups is shown when necessary 340 
by asterisks and was determined using one-way Anova followed by Dunett’s multiple 341 
comparison tests (*** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05). Median number of oocysts 342 
with 25%-75% percentile range is indicated above each column.  343 
 344 
Figure 2 345 
A and B. Expression pattern of nuclear, secreted and micronemal markers in 346 
control and treated parasites. 347 
Indirect Immunofluorescence detection of a nuclear (SET), secreted (P28) (panel A) 348 
and micronemal (SOAP) (panel B) protein in control and compound treated parasites. 349 
SET distribution did not show any difference in the treated compared to untreated 350 
parasites apart from nelfinavir treated ookinetes. P28 localisation was membrane and 351 
cytoplasmic in the treated parasites in contrast with the intense membrane staining of 352 
control parasites. Scale bar indicates 5 μΜ.  353 
C. Ultrastructural analysis of control and compound treated parasites. 354 
TEM images of HIV-PIs and Eer-related compound treated parasites. All drugs used 355 
at 35 μM apart from NA that was used at 10 μM. In the case of nelfinavir treatment 356 
parasites exhibit prominent nucleoli (asterisk) and enlarged nuclei. Eer, CBU-028 and 357 
NA treated parasites show an extended membrane structure around the nucleus 358 
(white arrows). Abbreviations: Nucleus; N. Scale bar indicates 2 μM. 359 
 360 



